Insight Molecular Diagnostics Inc. — Director's Dealing 2016

Sep 8, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2016-08-29

Reporting Person: BROADWOOD PARTNERS LP (10% Owner)
Reporting Person: BROADWOOD CAPITAL INC (10% Owner)
Reporting Person: BRADSHER NEAL C (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	2631681	Direct
Common Stock, no par value	2631681	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant to Purchase Common Stock	$3.25		Common Stock (1538462)		Direct
Warrant to Purchase Common Stock	$3.25		Common Stock (1538462)		Indirect

Footnotes

F1: These securities are owned by Broadwood Partners, L.P., which is a Reporting Person.

F2: The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: These warrants will become exercisable on the earlier of November 28, 2016 or the date shareholders approve the issuance of shares of Issuer common stock upon exercise of the warrants, and may be exercised for five years from the date they become exercisable.